Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

February 23, 2021February 23, 2021

Prolaris Test Helps ID Higher-risk Patients Who May Safely Skip ADT

News

Prolaris — a genetic test that predicts the aggressiveness of prostate cancer — can accurately identify which men with intermediate- or high-risk disease will benefit from adding androgen deprivation therapy (ADT) ... Read more

February 10, 2021February 10, 2021

New AI Tool May Better Predict Relapse After Surgery

News

Researchers have developed an artificial intelligence (AI) tool that shows the potential to predict prostate cancer aggressiveness and the likelihood of post-surgery relapse more accurately than standard methods can. Called ... Read more

November 12, 2020November 12, 2020

UK Study to Assess Causes of Greater Prostate Cancer Risk Among Black Men

News

Enrollment has resumed in a five-year U.K. study investigating genetic factors behind the higher risk of prostate cancer in men of African and Caribbean descent. The study involves researchers at ... Read more

October 20, 2020October 20, 2020

Provenge Improves Survival in mCRPC Patients Over Xtandi, Zytiga, Real-world Study Finds

News

Provenge (sipuleucel-T), by Dendreon Pharmaceuticals, is superior to Zytiga (abiraterone acetate) or Xtandi (enzalutamide) at prolonging the lives of men with metastatic castration-resistant prostate cancer (mCRPC) when added at any ... Read more

September 22, 2020September 22, 2020

Lynparza’s Approval Favored in EU for mCRPC Patients with BRCA Mutations

News

Lynparza (olaparib) has been recommended for approval in the European Union to treat men with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in BRCA1 and BRCA2, two DNA repair genes. The marketing authorization application ... Read more

September 10, 2020September 10, 2020

NIH Grants Dartmouth Team $2.5M to Develop Device for Detecting Cancer Cells

News

A research team at the Thayer School of Engineering at Dartmouth received a $2.5 million grant to develop and test a device meant to help surgeons detect and remove prostate cancer ... Read more

August 4, 2020August 4, 2020

Cryotherapy May Ably Treat Intermediate-risk Prostate Cancer

News

Cryotherapy directed to the cancerous part of the prostate may be an effective and less invasive treatment option for men with intermediate-risk, unilateral prostate cancer, without the common side effects of ... Read more

June 23, 2020June 23, 2020

Recommendation Against PSA Routine Screening May Have Contributed to Higher Rates of Advanced PC

News

The U.S. rates of advanced prostate cancer continued to rise in men 50 and older after the U.S. Preventive Services Task Force (USPSTF) recommended in 2012 against prostate-specific antigen (PSA)-based ... Read more

June 11, 2020June 11, 2020

Xtandi Plus ADT Bolsters Survival in High-risk Patients, Phase 3 Trial Finds

News

Adding Xtandi (enzalutamide) to standard androgen deprivation therapy (ADT) significantly prolonged life by nearly a year for men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC), final data from a Phase ... Read more

March 23, 2020April 15, 2020

Combining Two Biopsy Methods Improves PC Diagnosis, Study Shows

News

Combining two methods of prostate biopsy — using one guided by magnetic resonance imaging (MRI) along with conventional ultrasound-guided biopsy — results in a more accurate detection of clinically significant ... Read more